New drug targets Hard-to-Treat prostate cancer in phase 2 trial
Disease control
Recruiting now
This study tests a new drug called FG-3246 in 75 people with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The drug is designed to find and attack cancer cells while sparing healthy ones. The goal is to see if it can slow cancer growth an…
Phase: PHASE2 • Sponsor: Kyntra Bio • Aim: Disease control
Last updated May 07, 2026 18:40 UTC